Table 1 Participant characteristics (n = 78).

From: Effects of lactotripeptide ingestion and physical activity intervention on the fatigue status of middle-aged and older adults: a randomized controlled trial

 

Placebo (n = 20)

LTP (n = 20)

Placebo + PA (n = 19)

LTP + PA (n = 19)

P

Age, years

63 ± 2

62 ± 2

64 ± 2

63 ± 2

0.94

Men, n (%)

6 (30)

7 (35)

6 (32)

6 (32)

0.99

Height, cm

158 ± 2

158 ± 1

158 ± 1

161 ± 2

0.62

Education, n (%)

0.46

 < 9 years

0 (0)

0 (0)

1 (5)

0 (0)

 

 < 13 years

6 (30)

2 (10)

6 (32)

4 (21)

 

 < 15 years

5 (25)

8 (40)

7 (37)

8 (42)

 

 ≥ 15 years

7 (35)

10 (50)

5 (26)

6 (32)

 

 Missing

2 (10)

0 (0)

0 (0)

1 (5)

 

Living arrangement, n (%)

0.20

 With others

18 (90)

19 (95)

18 (95)

15 (79)

 

 Alone

2 (10)

0 (0)

1 (5)

1 (5)

 

 Missing

0 (0)

1 (5)

0 (0)

3 (16)

 

Work, n (%)

0.79

 Not working

5 (25)

3 (15)

6 (32)

3 (16)

 

 Homemaker

3 (15)

7 (35)

3 (16)

6 (32)

 

 Full-time job

4 (20)

5 (25)

5 (26)

4 (21)

 

 Part-time job

5 (25)

5 (25)

3 (16)

2 (11)

 

 Others

1 (5)

0 (0)

1 (5)

2 (11)

 

 Missing

2 (10)

0 (0)

1 (5)

2 (11)

 

Family income (JPY), n (%)

0.92

 < 3 million

5 (25)

1 (5)

4 (21)

6 (32)

 

 3 million ≤, < 5 million

5 (25)

5 (25)

3 (16)

3 (16)

 

 5 million ≤, < 7 million

3 (15)

6 (30)

4 (21)

5 (26)

 

 7 million ≤, < 10 million

2 (10)

4 (20)

3 (16)

1 (5)

 

 10 million ≤

2 (10)

1 (5)

2 (11)

2 (11)

 

 Missing

3 (15)

3 (15)

3 (16)

2 (11)

 

Marriage, n (%)

0.90

 Yes

17 (85)

17 (85)

17 (90)

18 (95)

 

 No

2 (10)

2 (10)

1 (5)

0 (0)

 

 Missing

1 (5)

1 (5)

1 (5)

1 (5)

 

Post-menopause, n (%)

0.48

 Yes

12 (86)

12 (92)

12 (92)

12 (92)

 

 No

2 (14)

0 (0)

1 (8)

0 (0)

 

 Missing

0 (0)

1 (8)

0 (0)

1 (8)

 

Medication use

 Beta blocker, n (%)

0 (0)

1 (5)

1 (5)

0 (0)

0.56

 Calcium channel blocker, n (%)

1 (5)

1 (5)

4 (21)

1 (5)

0.21

 Antidyslipidemic medicine, n (%)

3 (15)

4 (20)

3 (16)

4 (21)

0.95

 Hypoglycemic medicine, n (%)

0 (0)

1 (5)

0 (0)

0 (0)

0.40

 Antianxiety agent, n (%)

1 (5)

0 (0)

0 (0)

0 (0)

0.40

Supplement compliance, %†

100.0 ± 0.0

99.6 ± 0.2

97.7 ± 0.9

96.4 ± 1.3*⁑

0.01

Participation rate in a weekly supervised session, %

–

–

92 ± 3

93 ± 5

0.91

  1. Data are shown as the means ± standard error or frequency counts (%). Placebo, placebo without physical activity intervention; LTP, lactotripeptide without physical activity intervention; placebo + PA, placebo with physical activity intervention; LTP + PA, lactotripeptide with physical activity intervention. *P < 0.05 vs. placebo group; ⁑P < 0.05 vs. LTP group. †Data available in 77 individuals.
Back to article page